Medpace Holdings, Inc.
- Last sale
- Nov 12, 2026 · -1.28%
- Market cap
- $18.36B
- 27.97M shares
- Filings
- 932
Q3 2026+20.0% FY25 yoy
Q3 2026+11.6% FY25 yoy
Q3 2026+19.7% FY25 yoy
Q3 2026derived+19.2% FY25 yoy
Q3 2026+21.0% FY25 yoy
Q3 2026−25.8% FY25 yoy
- $18.36B
- 35.5×
- 6.5×
- 31.4×
- 3.64%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2,530,234,000 | reported | |
| FY 2024 | 2024-12-31 | $2,109,054,000 | reported | |
| FY 2023 | 2023-12-31 | $1,885,842,000 | reported | |
| FY 2022 | 2022-12-31 | $1,459,996,000 | reported | |
| FY 2021 | 2021-12-31 | $1,142,377,000 | reported | |
| FY 2020 | 2020-12-31 | $925,925,000 | reported | |
| FY 2019 | 2019-12-31 | $860,969,000 | reported | |
| FY 2018 | 2018-12-31 | $704,589,000 | reported | |
| FY 2017 | 2017-12-31 | $436,152,000 | reported | |
| FY 2016 | 2016-12-31 | $421,582,000 | reported | |
| FY 2015 | 2015-12-31 | $359,059,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $917.39M | $917.39M | — | 28.38M sh | −6.8% | 134.5% |
| FY2024 | — | $169.87M | $169.87M | — | 30.47M sh | −1.0% | 29.7% |
| FY2023 | — | $144.02M | $144.02M | — | 30.76M sh | −0.9% | 36.3% |
| FY2022 | — | $847.85M | $847.85M | — | 31.05M sh | −11.9% | 241.4% |
| FY2021 | — | $62.10M | $62.10M | — | 35.23M sh | −1.4% | 26.4% |
Segments
LineFY2025ShareChange
United States$83.90M64%+4.0%
Europe, Belgium$23.00M18%+23.9%
Asia-Pacific$14.91M11%+2.5%
Europe, Other$6.82M5.2%−8.5%
Other$2.43M1.9%+2.9%
Total$131.06M
Commercial physical & biological research
Medpace Holdings, Inc. is the 5th largest of the 17 covered companies the SEC files under this code, by revenue. SIC 8731
CompanyRevenueGrowthNet marginMarket cap
IQVIQVIA Holdings Inc.$16.3B5.9%8.3%$44.7BICLRIcon PLC$8.3B0.8%2.8%—INCYIncyte Corp$5.1B21.2%25.0%$24.8BCRLCharles River Laboratories International, Inc.$4.0B0.9%3.6%$16.9B
MEDPMedpace Holdings, Inc. (this company)$2.5B20.0%17.8%$18.4B
NRCNRC Health$137.4M4.0%8.4%$566.4MMXCTMaxcyte, Inc.$33.0M14.5%135.1%$121.8MOABIOmniAb, Inc.$18.7M29.3%347.0%$721.3MFOXOFoxo Technologies Inc.$16.4M304.0%75.9%—Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Medpace Holdings, Inc. · CIK 1668397 · Engraved from SEC EDGAR